View this API's:

Patents at Patent & Trademark Office Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… Lipitor (atorvastatin calcium) tablets, Parke-Davis Pharmaceutical Research, agent for Warner-Lambert Export, Limited NDA 20-702 /S-003/S-005 7/10/98 7/10/98 11/12/98 Lipitor Indications: S-003 provides for the use of Lipitor as an adjunctive therapy to diet for the treatment of patients with elevated serium triglyceride levels (Frederickson Type IV). S-005 provides for the use of Lipitor by patients with primary dysbetalipoproteinemia (Frederickson Type III) who do not respond adequately to diet. Lipitor (atorvastatin calcium) tablets, Parke-Davis Pharmaceutical Research, agent for Warner-Lambert Export, Limited NDA 20-702 /S-004 2/2/98 10/23/98 Lipitor (atorvastatin calcium) tablets, Parke-Davis Pharmaceutical Research, agent for Warner-Lambert Export, Limited NDA 20-702 /S-14 8/28/98 12/14/98 Lipitor (atorvastatin calcium) tablets, Parke-Davis, agent for Warner-Lambert Export, Limited NDA 20-702 /S-18 12/2/99 12/29/99 4/23/03 Lipitor (atorvastatin calcium) Tablets, Pfizer Ireland NDA 20-702 /S-25 6/15/01 11/6/01 11/6/01 4/10/02 Lipitor (atorvastatin calcium) Tablets, Pfizer, NDA 20-702/S-33 10/18/02 10/28/02 10/18/02 Lipitor (atorvastatin calcium) Tablets, Pfizer Ireland NDA 20-702 /S29 & S34 4/22/02 5/2/02 4/24/02 Lipitor (atorvastatin calcium) Tablets, Pfizer NDA 20-702/S37 9/29/03 10/9/03 10/10/03 Lipitor (atorvastatin calcium) Tablets, Pfizer NDA 20-702/S36 Caduet (amlodipine besylate/atorvastatin calcium) Tablets, Pfizer Inc. Lipitor (Atorvastatin calcium) tablets, Pfizer Lipitor (Atorvastatin calcium) tablets, Pfizer Inc., New or Modified Indication   For the latest approval information, locate this drug using this index.